Analysts say pharma may escape near-term hit from Trump tariffs
4 Articles
4 Articles
FTSE 100 pharma giants GSK and Astrazeneca appear to swerve Trump tariffs
FTSE 100 pharma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a City broker. Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his Rose Garden ‘Liberation Day’ address on Wednesday, but there is still uncertainty about the impact on the sector. This is according to a new research note from Shore Capital, which has spoken to FTSE 100-lis…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage